Llusern Scientific is a manufacturer of molecular diagnostic testing for use in near-patient settings.

Llusern’s testing platform, Lodestar DX, uses LAMP technology to amplify and detect DNA and RNA to identify a wide range of bacterial and viral targets.

Lodestar DX has a small footprint, a low manufacturing cost and is suitable for a variety of human clinical applications including testing for Urinary Tract Infections (UTI).

Llusern’s UTI test panel can identify the presence of six pathogens in one microlitre of urine. UTIs are a global healthcare problem with an estimated 400m confirmed cases every year. Despite this prevalence there are very few diagnostic tools currently available for UTIs.

The need for better diagnosis of UTIs is exacerbated by the need to reduce the volume of antibiotics prescribed for suspected cases in order to counter the impact of antimicrobial resistance (AMR). AMR is considered to be a healthcare timebomb by the global professional medical community.

The Lodestar UTI testing system is UK CA marked and the company holds ISO 13485 certification. Lodestar will obtain CE-IVDR in the course of 2026. Llusern is looking for suitable distributors in the Middle East region during WHX.